Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Travere Therapeutics Inc (NQ: TVTX ) 9.970 +0.180 (+1.84%) Streaming Delayed Price Updated: 10:01 AM EDT, Jul 12, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 103,248 Open 9.900 Bid (Size) 9.950 (2) Ask (Size) 9.990 (3) Prev. Close 9.790 Today's Range 9.833 - 10.05 52wk Range 5.120 - 17.57 Shares Outstanding 60,717,176 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 10 Health Care Stocks Whale Activity In Today's Session July 10, 2024 Via Benzinga Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday July 09, 2024 Via Benzinga Performance YTD +4.29% +4.29% 1 Month +41.02% +41.02% 3 Month +49.03% +49.03% 6 Month +10.90% +10.90% 1 Year -35.64% -35.64% More News Read More Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference July 08, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 11, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Expert Outlook: Travere Therapeutics Through The Eyes Of 6 Analysts May 07, 2024 Via Benzinga Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know April 17, 2024 Via Benzinga Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 15, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress May 09, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at Upcoming Investor Conferences May 08, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Peeling Back The Layers: Exploring Travere Therapeutics Through Analyst Insights March 13, 2024 Via Benzinga Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (7 Ratings) February 16, 2024 Via Benzinga Earnings Scheduled For February 15, 2024 February 15, 2024 Via Benzinga TVTX Stock Earnings: Travere Therapeutics Misses EPS, Misses Revenue for Q1 2024 May 06, 2024 Via InvestorPlace Travere Therapeutics Reports First Quarter 2024 Financial Results May 06, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Report First Quarter 2024 Financial Results April 29, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy April 24, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Earnings Preview For Travere Therapeutics February 14, 2024 Via Benzinga Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International April 04, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association April 03, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 13, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN) March 11, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at Upcoming Investor Conferences February 26, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy February 23, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results February 15, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results February 08, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
